Balchem Corporation (BCPC) Stock Price & Analysis
Balchem Corporation (BCPC) closed at USD 173.23 on Thursday, October 22, 2026, up 1.43% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 170.78; the Oct 22, 2026 session ranged USD 170.54–173.43 on volume of 491,675 shares. Market capitalization is $5.52B, with a 52-week range of USD 147.18–183.9 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:01 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BCPC.md
Key facts (BCPC)
- Last four reported quarters (through Jun 30, 2026): revenue $1.09B, net income $164M (15.1% margin) (SEC filings).
- Valuation: P/E 33.6x (avg 39.4x at the last 3 fiscal year-ends).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (3 analysts), mean target USD 209.25 (range 165–242).
- Total return with dividends: 1Y +11.2% vs S&P 500 +14.9%; 5Y +14.9% vs S&P 500 +80.3%.
- Next earnings: 2026-10-23, EPS estimate USD 1.54, revenue estimate $289M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BCPC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $799M | $942M | $922M | $954M | $1.04B | $1.09B |
| Gross profit | $243M | $280M | $302M | $336M | $371M | — |
| Operating income | $128M | $145M | $159M | $183M | $209M | $222M |
| Net income | $96.1M | $105M | $109M | $128M | $155M | $164M |
| EPS (diluted) | $2.94 | $3.25 | $3.35 | $3.93 | $4.75 | — |
| Free cash flow | $124M | $89.5M | — | — | — | — |
| Gross margin | 30.4% | 29.8% | 32.7% | 35.3% | 35.7% | — |
| Operating margin | 16.0% | 15.4% | 17.3% | 19.2% | 20.2% | 20.4% |
| Net margin | 12.0% | 11.2% | 11.8% | 13.5% | 14.9% | 15.1% |
| Revenue growth | +13.6% | +17.9% | -2.1% | +3.4% | +8.8% | — |
| Cash + short-term investments | $103M | $66.6M | $64.4M | $49.5M | $74.6M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BCPC)
P/E 33.6x · P/S 5.1x · P/B 4.2x · Earnings yield 2.98% · Dividend yield (paid, TTM) 0.56% · Buyback yield (TTM) 2.06%
P/E at fiscal year-ends: Dec 2025 32.3x, Dec 2024 41.5x, Dec 2023 44.5x.
Analysts (BCPC)
Consensus Buy (mean 2.00 on a 1–5 scale), 3 analysts; mean target USD 209.25 (low 165, high 242).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-03 | HC Wainwright & Co. | Target raised | Buy | $190 → $215 |
Total return (dividends reinvested) (BCPC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +11.2% | +14.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +11.2% | +2.8% |
| Volatility (annualized) | 20.3% | 24.0% |
| Max drawdown | -14.7% (Mar 2026→Jun 2026) | -32.0% (Dec 2021→Jun 2022) |
BCPC revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Human Nutrition and Health | $176.9M | 62.3% | +10.0% |
| Animal Nutrition and Health | $64.5M | 22.7% | +15.0% |
| Specialty Products | $40.5M | 14.3% | +8.9% |
| Total revenue | $284.0M | 100% | — |
BCPC revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product Sales Revenue | $283.4M | 99.8% | +11.1% |
| Royalty Revenue | $634,000 | 0.2% | +48.8% |
| Total revenue | $284.0M | 100% | — |
BCPC revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $205.2M | 72.3% | +9.9% |
| Non-US | $78.8M | 27.7% | +14.6% |
| Total revenue | $284.0M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
BCPC suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Related party | Gabriel CC Company | “We were engaged in related party transactions with St. Gabriel CC Company, LLC for the years ended December 31, 2025 and December 31, 2024.” |
Quoted from the company's 10-K filed Feb 20, 2026.
BCPC company outlook (results filed Jul 31, 2026)
- “Ted Harris said, "The Balchem team delivered another strong quarter in Q2 of 2026, and we remain confident in the long-term growth outlook for our company as we continue to execute our strategic growth initiatives." (b) Net debt is defined as the outstanding balance on our revolving loan less cash and cash equivalents.”
- “Forward-Looking Statements This release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties.”
Quoted word-for-word from the SEC 8-K results press release.
BCPC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.53 | $1.50 | +2.0% | $289.2M | 2 |
| Next quarter (ends Dec 2026) | $1.47 | $1.44 | +2.1% | $287.8M | 2 |
| Current fiscal year (ends Dec 2026) | $5.84 | $5.68 | +2.7% | $1.13B | 3 |
| Next fiscal year (ends Dec 2027) | $6.27 | $6.11 | +2.7% | $1.20B | 3 |
Key Statistics (as of October 23, 2026 at 10:01 UTC)
| Price | USD 173.23 |
|---|---|
| Change | ▲ 1.43% (up) |
| Previous Close | USD 170.78 |
| Open | USD 170.68 |
| Day Range | USD 170.54 – 173.43 |
| 52-Week Range | USD 147.18 – 183.9 |
| Volume | 491,675 shares |
| Market Cap | $5.52B |
| Exchange | NMS |
Technical Analysis (BCPC)
Nexqual's technical model rates BCPC "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 10:01 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.41 (neutral) |
| vs SMA50 | Above (USD 171.13) |
| MACD | 0.69 (positive) |
Analyst Ratings (BCPC)
Wall Street analysts rate BCPC "Buy" based on 3 analysts, with a mean price target of USD 209.25 (range USD 165–242), per Nexqual as of October 23, 2026 at 10:01 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 209.25 |
| High Target | USD 242 |
| Low Target | USD 165 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (BCPC)
| Next Earnings Date | 2026-10-23 |
|---|---|
| EPS Estimate | USD 1.54 |
| Revenue Estimate | $289.25M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.49 vs est 1.43 ▲ beat |
| 2026-03-31 | USD 1.33 vs est 1.33 ▲ beat |
| 2025-12-31 | USD 1.31 vs est 1.29 ▲ beat |
| 2025-09-30 | USD 1.35 vs est 1.31 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Financials & Fundamentals (BCPC)
| Total Revenue | $1.09B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +11.20% |
| Gross Margin | +36.29% |
| Operating Margin | +20.85% |
| Profit Margin | +15.14% |
| ROE | +12.79% |
| Debt / Equity | 0.13 |
| Current Ratio | 2.67 |
| Total Cash | $63.17M |
| Total Debt | $166.72M |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Financial Health Score (BCPC)
Nexqual rates Balchem Corporation's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:01 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 36%, operating 21% (last 12 months) |
| Balance Sheet | Strong — $63M cash vs $167M debt |
| Cash Flow | Solid — Operating cash flow $217M (FY ended Dec 2025, 10-K) |
| Efficiency | Mixed — ROE 13%, ROA 8.2% |
Ownership (BCPC)
| Insider Ownership | +0.49% |
|---|---|
| Institutional Ownership | +93.44% |
| Shares Outstanding | 31.88M |
| Float | 31.69M |
| Short % of Float | +2.12% |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
Leadership (BCPC)
Balchem Corporation is led by Theodore Lee Harris, CEO, President & Chairman, per Nexqual as of October 23, 2026 at 10:01 UTC.
| CEO, President & Chairman | Theodore Lee Harris |
|---|---|
| Executive VP, CFO, Treasurer and GM of Animal Nutrition & Health | Carl Martin Bengtsson |
Major Backers & Investors (BCPC)
Notable institutional backers of Balchem Corporation include Conestoga Capital Advisors, LLC, Morgan Stanley, Geneva Capital Management LLC, according to Nexqual as of October 23, 2026 at 10:01 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Conestoga Capital Advisors, LLC | 3.41% |
| Morgan Stanley | 2.62% |
| Geneva Capital Management LLC | 2.14% |
| Wasatch Advisors LP | 1.98% |
| First Trust Advisors LP | 1.94% |
| First TRT Exch-Trd Fd. VI-First TRT SMID Cap Rising Dividend Achievers | 1.8% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 15.57% |
| Vanguard Group | 11.5% |
| State Street | 4.02% |
| Geode Capital | 3.52% |
Source: Nexqual, October 23, 2026 at 10:01 UTC.
From Balchem Corporation's Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- We currently hold over 130 patents and over 400 registered trademarks in the United States and overseas.
- Formulae and know-how are of particular importance in the manufacture of a number of our proprietary products.
- Factors we consider in determining the products to pursue include projected markets and needs, status of our proprietary rights, technical feasibility, expected and known product attributes, and estimated costs to bring the product to market.
Partnerships
- The Company's inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment.
Legal & Regulatory Risks (Item 1A, quoted)
- We may from time to time become involved in various legal proceedings and disputes incidental to the operation of our business.
- Our business exposes us to potential product liability claims and recalls, which could adversely impact our financial condition and performance.
- Our brands are important assets of our businesses, and violation of our trademark rights by imitators could negatively impact revenues and brand reputation.
- We may be subject to claims of infringement of intellectual property rights by third parties.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SXT | Sensient Technologies Corporati | USD 130.94 | ▼ 0.95% |
| EMN | Eastman Chemical Company | USD 65.31 | ▲ 2.85% |
| AXTA | Axalta Coating Systems Ltd. | USD 35.05 | ▲ 0.2% |
| NEU | NewMarket Corp | USD 876.33 | ▼ 0.98% |
| ESI | Element Solutions Inc. | USD 33.11 | ▼ 8.89% |
| WLK | Westlake Corporation | USD 64.14 | ▲ 5.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:01 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt